Webinar: ADC’s Are Back Stronger Than Ever: How, Why & What’s Next
Summary: Antibody-drug conjugates (ADCs) have achieved commercial success over the last ten years. ADCs offer the prospect of more precise treatments and a reduction in off-target effects, however challenges including instability remain. In this on-demand presentation, Mike Riley, President, 91Ï㽶ÊÓƵ Biologics, will discuss the latest trends in ADC discovery and development, with a focus on how next generation pipelines are being shaped by payload and linker chemistry innovations, including those from 91Ï㽶ÊÓƵ’s award-winning SMARTag® ADC platform.